DiMarchi, who was a vice president at Eli Lilly and involved in GLP-1 research there, until he left the company in 2003, is that many diseases may share the same root causes, even though we label them and treat them as distinct: This is an endocrine disease, this is a cardiovascular disease, this is a brain disease. This root-cause theory suggests that a wide range of conditions can be treatable with one drug class, sometimes through pathways in the brain and the immune system
Caregivers should also watch for signs that nutritional intake is becoming inadequate, including: excessive fatigue worsening weakness noticeable muscle loss hair thinning frequent skipped meals Since many older adults may not feel hungry, it can be helpful to offer smaller, protein-rich meals and snacks on a regular schedule rather than waiting for hunger cues
TripleHormone-Receptor agonist Retatrutide for Obesity A phase 2 trial
Initial weight loss with GLP-1 receptor agonists typically becomes noticeable within the first 48 weeks of treatment, though the timeline varies considerably between individuals